News

AGMB
AgomAb Therapeutics NV News

This news view pulls recent coverage and headlines tied to AGMB.

Latest Close

$11.50

1y Change

-$3.15 (-21.50%)

Market Cap

$566,351,744.00

Sector

Healthcare

Industry

Biotechnology

Recommendation

none

Agomab to Participate in Upcoming Conferences

GlobeNewswire • May 14, 2026

Read article

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

GlobeNewswire • Apr 23, 2026

Read article

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

Insider Monkey • Apr 12, 2026

Read article

AgomAb Says Investigational Fibrosis Drug AGMB-447 Receives US Patent

MT Newswires • Mar 26, 2026

Read article

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire • Mar 26, 2026

Read article